CBD and Down-Scheduling in Australia

Twelve products. That's roughly how many low-dose CBD preparations had cleared the Australian Register of Therapeutic Goods (ARTG) as full over-the-counter listings in the two years after the February 2021 down-scheduling decision. Not the flood that headlines predicted. I keep a running count because I reckon the gap between the policy story and the pharmacy shelf reality is the most under-reported angle in Australian cannabis regulation.

So let's work through what actually happened, what the legal architecture looks like right now, and why "over-the-counter CBD" is still, in most practical senses, a theoretical category.

What down-scheduling means in the Poisons Standard

Australia's scheduling regime sits inside the Poisons Standard (the current instrument is formally titled the Standard for the Uniform Scheduling of Medicines and Poisons, made under the Therapeutic Goods Act 1989). Each schedule carries a different access tier. Schedule 4 (Prescription Only) requires a valid prescription; Schedule 8 (Controlled Drug) sits above that with additional state-level controls around record-keeping and prescriber authority.

Before 2021, essentially all cannabidiol (CBD) products were Schedule 4, meaning prescription-only access. The TGA's delegate decision of February 2021 created a new, narrow Schedule 3 (Pharmacist Only) entry for CBD. Not Schedule 2, not unscheduled , Schedule 3, meaning a pharmacist must be present and can intervene in the supply.

The conditions attached to that Schedule 3 entry are strict. Products must contain 150 mg/day or less of CBD as the maximum recommended dose. They must contain 1% w/w or less of other cannabinoids , so virtually no THC, no meaningful CBG, nothing that tips the formulation toward a broader cannabinoid profile. And crucially, the product must be included on the ARTG as an approved over-the-counter medicine before a pharmacist can lawfully supply it.

That last condition is where the bottleneck lives.

The ARTG registration requirement , and why it's a real hurdle

Getting a medicine onto the ARTG is not a formality. For a registered (as opposed to listed) medicine, a sponsor must submit a full dossier of safety, quality, and efficacy data that meets TGA evidentiary standards. For a listed medicine; a lower tier, the product must contain only pre-approved ingredients at accepted doses, and sponsors self-certify compliance, though the TGA audits.

Low-dose CBD didn't neatly fit the existing listed-medicine ingredient framework when the 2021 decision landed. Sponsors wanting to market a Schedule 3 CBD product had to navigate the registration or listing pathway, manufacturing under Good Manufacturing Practice (GMP) standards, with the product's full formulation sitting on the public register. That's a significant investment. For smaller operators it was, bluntly, a wall.

The TGA has acknowledged the pathway is underutilised. Their published review materials from 2023 note that while the scheduling change was designed to improve access, the commercial and regulatory costs of ARTG inclusion have slowed market entry. I'd argue this was predictable from the moment the decision was drafted, the scheduling change created legal permission without dismantling the upstream barriers. Those are two different things.

What stayed in Schedule 4 (and Schedule 8)

The down-scheduling only carved out that narrow low-dose band. Everything else; higher-dose CBD products, any product with meaningful THC content, and all medicinal cannabis products that don't meet the 150 mg/day and 1% cannabinoid purity criteria, remained prescription-only (Schedule 4) or, where THC content is significant, Schedule 8.

This means the vast majority of medicinal cannabis products currently accessed by Australians still move through prescription channels: either via the Special Access Scheme (SAS), under which unapproved products can be prescribed for individual patients, or through the Authorised Prescriber pathway, which allows a clinician with TGA approval to prescribe a specific unapproved product to a class of patients without a per-patient SAS application.

SAS Category B approvals for medicinal cannabis have grown substantially year-on-year, the TGA's own published data showed approvals tracking in the hundreds of thousands annually by the mid-2020s. That growth is the real access story; the Schedule 3 pathway has been comparatively quiet.

CBD's pharmacology: why schedule matters for formulation

Worth pausing here on the chemistry, because the 1% co-cannabinoid cap has real formulation implications. CBD doesn't exist in isolation in the plant; it's biosynthesised alongside dozens of other compounds. A full-spectrum extract retains THC, terpenes, minor cannabinoids; a broad-spectrum extract removes THC but keeps the rest; an isolate is purified CBD only.

The Schedule 3 pathway essentially mandates something close to isolate or highly purified broad-spectrum, because the 1% co-cannabinoid ceiling is very tight. Researchers studying the entourage effect, the hypothesis that cannabinoids and terpenes may interact in ways that differ from isolated compounds, would note this is a meaningful constraint on what Schedule 3 products can look like chemically. Whether that matters clinically at low doses is an open research question; I'm not making a therapeutic claim here, just flagging that the scheduling criteria have a direct read-through to formulation chemistry.

CBD itself interacts with the endocannabinoid system, though its binding profile differs from THC; it has low affinity for the canonical CB1 receptor that THC engages with strongly, and its pharmacology involves a broader set of receptor targets. Understanding how orally administered CBD is absorbed and metabolised also requires looking at first-pass metabolism, which significantly reduces bioavailability for standard oral formulations, relevant context for dose thresholds in scheduling criteria.

State and territory overlay

Australian scheduling is a Commonwealth instrument, but supply of medicines also intersects with state and territory poisons legislation. Each jurisdiction adopts the Poisons Standard (or a version of it) into local law, and state-level provisions can add requirements around record-keeping, prescription form, or pharmacist authorisation. For Schedule 8 medicinal cannabis, products with significant THC content; state-specific approvals may be required on top of the Commonwealth scheduling and ARTG or SAS framework. Practitioners in the ACT, where I'm based, navigate the ACT Medicines, Poisons and Therapeutic Goods Act 2008 alongside TGA requirements. It's layered. That's the honest answer.

(I was out on the Stromlo Forest Park road loop last Saturday morning going through this in my head, there's something about a long climb that's good for untangling regulatory architecture. Didn't solve it, but the ride helped.)

What the 2021 decision did and did not do

The decision established that low-dose, pharmacist-supervised CBD is acceptable in principle as a non-prescription medicine in Australia, provided a sponsor has done the work to get a product ARTG-listed or registered. That's genuinely significant as a regulatory statement.

What it did not do: create immediate over-the-counter access, remove the manufacturing and quality compliance burden, or signal that CBD is without any regulatory oversight. The TGA has been consistent that scheduling and ARTG requirements are not bureaucratic formalities, they are the mechanism by which quality, safety, and accurate labelling are assured for medicines reaching consumers without clinician supervision.

For anyone trying to understand where a specific product sits legally, the ARTG public search tool at tga.gov.au is the primary reference. If a CBD product is not on the ARTG and is being sold without prescription in Australia, its legal supply status is, at minimum, complicated; and potentially a breach of the Therapeutic Goods Act 1989.

Where things stand now

The TGA continues to review access pathways for medicinal cannabis. Consultation processes through 2023 and 2024 have looked at whether the ARTG pathway barriers for Schedule 3 CBD could be reduced without compromising quality or safety standards. No major structural changes had been finalised as of early 2025, though the policy conversation is ongoing.

The broader medicinal cannabis market, Schedule 4 and Schedule 8, prescription-access, has meanwhile grown substantially, driven primarily by the SAS and Authorised Prescriber channels. That's where actual patient access is happening at scale.

The Schedule 3 story is still, in my read, unfinished. The regulatory permission exists. The practical pathway to market for sponsors remains demanding. Whether that changes depends on TGA policy decisions that haven't yet landed.

Sources

• Scheduling Delegate Final Decisions, February 2021; Therapeutic Goods Administration (TGA)
• About Medicinal Cannabis, Therapeutic Goods Administration (TGA)
• Poisons Standard (Standard for the Uniform Scheduling of Medicines and Poisons), Federal Register of Legislation
• Cannabidiol: Promise and Pitfalls; Neurotherapeutics, NCBI/NIH

, Marcus Hale, Regulatory researcher, TGA & access law

]]>